The major covalent adduct formed between a 13 C-labelled formaldehyde activated bis-amino mitoxantrone analogue (WEHI-150) and the hexanucleotide d(CG 5Me CGCG) 2 has been isolated by HPLC chromatography and the structure determined by NMR spectroscopy. The results indicate that WEHI-150 forms one covalent bond through a primary amine to the N-2 of the G 2 residue, with the polycyclic ring structure intercalated at the 5Me C 3 pG 4 /G 10 p 5Me C 9 site. Furthermore, the WEHI-150 aromatic ring system is oriented approximately parallel to the long axis of the base pairs, with one aliphatic side-chain in the major groove and the other side-chain in the minor groove. This study indicates that mitoxantrone derivatives like WEHI-150 should be capable of forming major-minor groove cross-linked adducts that will likely produce considerably different intracellular biological properties compared to known anthracycline and anthracenedione anticancer drugs. 
Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts
Introduction
The dose-limiting toxicities of the anthracycline class of anticancer drugs (e.g. doxorubicin) have promoted the search for new anthracenedione derivatives with comparable cytotoxicity but lower cardiotoxicity. Mitoxantrone (see Fig. 1 ) is a synthetic second-generation anthracycline derivative that is clinically used for the treatment of a variety of cancers. [1] [2] [3] It exhibits significantly lower cardiotoxicity than the anthracyclines but maintains potent anticancer activity. 4, 5 Mitoxantrone and related derivatives can bind DNA by intercalation and induce a cytotoxic effect through the impairment of topoisomerase II. 6, 7 More recently, it has been demonstrated that mitoxantrone can also form a covalent adduct at the N-2 amino group of a guanine nucleotide in DNA, after activation of a side-chain amine by formaldehyde, that potentially leads to apoptosis independently of topoisomerase II-mediated damage. 8, 9 However, the mitoxantrone-DNA covalent adduct is yet to be structurally characterised. The atom numbering of WEHI-150 is given.
WEHI-150 is a bis-amino mitoxantrone analogue (see Fig. 1 ) that contains two potentially reactive amine groups in each side-chain. As a consequence WEHI-150 can more rapidly and more extensively form covalent adducts with DNA than mitoxantrone. 10 In order to further develop the anthracenedione class of anticancer drugs it is important to determine the structure of a mitoxantroneor mitoxantrone derivative-DNA adduct. Previous studies have demonstrated that WEHI-150 preferentially intercalates and then forms covalent adducts with DNA at CpG sites. 10 In addition, WEHI-150 forms significantly more covalent adducts when the cytosine at the CpG site is methylated at the C-5 position ( 5Me CpG). 10 Consequently, we sought to isolate by HPLC the major covalent adduct formed between WEHI-150 and the hexanucleotide d(CG 5Me CGCG) 2 and then examine its structure by NMR spectroscopy.
Materials and methods
The oligonucleotide d(CG 5Me CGCG) 2 was obtained from GeneWorks, South Australia, and WEHI-150 was synthesised as previously described. 11 The covalent adduct was produced by incubating the The molecular modelling investigations were carried out using HyperChem Release 7.5 software as previously described. 10 Duplex B-DNA was generated from the nucleic acid database. Energy ) were then applied to maintain a maximum distance of 3.5 Å between any drug and oligonucleotide protons that gave strong NOEs in the NOESY spectra. The drugoligonucleotide complex was then energy minimised using the AMBER 99 molecular mechanics optimisation process. The distance restraints were then removed and the structure re-optimised to obtain a local energy minimum.
Results and discussion
In preliminary experiments, the reactions of WEHI-150 with guanosine, guanosine monophosphate Experiments were carried out to determine the stability of the major covalent adduct as a function of pH (after a 12-hour incubation) and incubation time at pH 7.0. The percentage of remaining intact covalent adduct was determined by HPLC with UV detection. The results showed that the adduct was more stable at basic pH compared to acidic conditions. No adduct was observed after a 12-hour incubation at pH 3.1 at 37 °C, whereas approximately 75% of the adduct remained intact at pH 7,
indicating the WEHI-150-d(CG 5Me CGCG) 2 adduct was moderately stable at neutral pH. The covalent adduct was incubated at 37 °C in 10 mM phosphate buffer at pH 7.0 and the amount of remaining intact covalent adduct monitored by HPLC at different time intervals. Approximately 50% of the covalent adduct was observed after 33 hours incubation at 37 °C, indicating that the covalent adduct was highly stable compared to the parent drug mitoxantrone. 12 It was also noted that WEHI-150-d(CG 5Me CGCG) 2 adduct appeared to be degraded to free DNA.
Mass spectrometry was used to identify the number of WEHI-150 molecules and the number of A relatively strong NOE was observed between the H2 of WEHI-150 and the oligonucleotide 5Me C 3 methyl protons, whereas, only a weak NOE was observed between the H3 and the 5Me C 3 methyl protons. In contrast, a strong NOE was noted between the H3 and the 5Me C 3 H2′′ protons and a weak NOE between the H2 and 5Me C 3 H2′′. These observations suggest the H3 proton is located under the 5Me C 3 base whereas the H2 proton is positioned more towards the major groove of the oligonucleotide.
Of further note, NOEs of medium intensity were observed from the WEHI-150 H6/H7 protons to the oligonucleotide 5Me C 9 H6 and 5Me C 9 CH 3 protons. Observation of NOEs from the WEHI-150 H2, H3
and H6/H7 protons to only major groove oligonucleotide protons suggests that the long axis of the polycyclic ring system of WEHI-150 is positioned more parallel, than perpendicular, to the base pairs at the intercalation site. Consistent with this proposition was the observation of NOEs from the aliphatic side-chain protons to both major ( 5Me C 9 H6 and 5Me C 9 CH 3 ) and minor groove (G 2 H1′ and can be further concluded that the covalent adduct was formed through the reaction of a primary sidechain amine group.
Taken together the MS and NMR results indicate that WEHI-150 forms one covalent bond through a primary amine to the N-2 of the G 2 residue, with the polycyclic ring structure intercalated at the 5Me C 3 pG 4 /G 10 p 5Me C 9 site. Furthermore, the WEHI-150 aromatic ring system is oriented approximately parallel to the long axis of the base pairs, with one aliphatic side-chain in the major groove and the other side-chain in the minor groove. Although the NMR data was not sufficient to allow the determination of the structure of the covalent adduct by restrained molecular dynamics, simple energy minimised (to remove steric clashes) models could be constructed that were consistent with the NMR data. The model shown in Fig. 5 indicates that the proposed "threaded" structure (aliphatic side-chains in major and minor grooves) is feasible. Models were constructed keeping both aliphatic side chains in the minor groove as observed with the reversible binding; 10 however, the resultant models were not consistent with the observed NOEs and thus the models were discounted (e.g. see ESI Fig. S4 †) . A number of compounds, both organic (e.g. nogalamycin) and transition metal complexes (e.g. dinuclear ruthenium complexes), have been reported to bind DNA in a threaded intercalative manner.
14-17 The structures of formaldehyde-cross-linked adducts of the anthracyclines daunorubicin and doxorubicin with oligonucleotides have been previously reported; 18, 19 however, this study reports for the first time (to our knowledge) the structure of a mitoxantrone analogue-DNA covalent adduct.
Although the anthracycline-DNA adducts contain a CH 2 link to the N-2 of a guanine residue, the polycyclic ring system is positioned perpendicular to the base pairs at the intercalation site in a similar manner to that found for the reversibly bound drugs. 20 Furthermore, the entire covalently bound anthracycline drug resides in the DNA minor groove.
The results of this study indicate that WEHI-150 remains intercalated at the 5Me CpG site and forms a covalent link through a methylene group to the N2-amino group of a guanine residue adjacent to the intercalation site. However, and interestingly, the NMR results were only consistent with a threaded structure where the WEHI-150 has one side-chain in the major groove and the other in the minor groove. Furthermore, the results clearly demonstrated that the primary amine of WEHI-150 was significantly more reactive than the secondary amine. This suggests a mitoxantrone derivative with an amine in each side-chain, with extended methylene chains, might be the optimal anthracenedione.
Furthermore, the addition of asymmetric side-chains may yield an anthracenedione capable of facilitating dual covalent bond formation, and thus higher stability as well as posing a greater challenge for cellular DNA repair responses. In particular, our work raises the likelihood that the threaded structure is capable of covalent linkages in both the DNA minor and major grooves. In a previous study, 10 it was found that one WEHI-150 could form adducts with one, two and even three CH 2 covalent links to an oligonucleotide. Consequently, it is likely that one of the amine groups located in the major groove by the threaded structure can form a covalent link, after activation by formaldehyde, with a nucleophilic nitrogen (e.g. the N7 of a guanine residue) in the major groove.
Additionally, in order to potentially increase the proportion of such a major-minor groove covalent cross-linking drug, novel mitoxantrone analogues can now be envisioned that contain an electrophilic carbon on one side-chain (through replacement of the terminal amine with a CH 2 -Cl) that would more readily react with nucleophilic groups in the DNA major groove.
In conclusion, the threaded adduct structure we have observed for the mitoxantrone analogue WEHI-150, and the proposed major-minor groove cross-linked adduct (a new type of drug-DNA binding motif) will likely produce considerably different intracellular biological properties compared to anthracycline-DNA covalent adducts. For example, the stabilised threaded structure is more likely to inhibit transcription due to interfering with the binding of transcription factors in the DNA major groove.
